The PRWIRE Press Releases https:// 2017-11-14T00:49:44Z Women Entrepreneur Closing Regional and STEM Gender Gaps 2017-11-14T00:49:44Z women-entrepreneur-closing-regional-and-stem-gender-gaps Household names such as Booktopia, Carmens Fine Foods and Cellarmasters started as AFR Fast 100 companies. Now a Dubbo entrepreneur closing regional and gender gaps has earned her place on the list, as one of the country’s fastest growing businesses. Meet Juliet Duffy of Regional Enviroscience. Nine years ago Juliet Duffy started this business from a garage in a rental property in Dubbo, NSW. Now, with offices in Dubbo, Wagga and Tamworth and recently in Maroochydore, Queensland, her business employs over 25 people, including 17 professional staff. Regional EnviroScience is an Occupational and Environmental Hygiene consultancy with specialties in asbestos, pollution incidents, meth lab clean-ups, contaminated sites and air, & water monitoring. EnviroScience protects the health of people and the environment through detecting and monitoring a range of contaminants in the air, water, soil and materials working with a range of public and private clients including state & federal departments and tier one civil, manufacturing and mining companies. ‘Being regionally-based,’ says Juliet Duffy, ’we understand the uniqueness of our natural environment, infrastructure and communities. Living in the towns where we work, our team has the connections and support to get the job done quickly and efficiently, and recognition of our innovative approach to meeting legislative and safety requirements has amplified our growth’. The company also specialises in naturally occurring asbestos which is prevalent in regional NSW, detecting and testing samples at their Dubbo-based NATA accredited laboratory. Typically a male dominated industry, the EnviroScience team includes two young women who are both science qualified and Licenced Asbestos Assessors, mentored by Juliet. ‘Being a woman in STEM is not without its challenges – especially with perceptions, however it has never really been a problem with on-site work’ says Juliet, ‘all of our team, contractors and clients support each other in day to day operations. It has been easy and thoroughly enjoyable to grow the business to where it is today, and without their support we wouldn’t have been able to achieve this extraordinary growth. I thank them all.’ The growth over the last four years can also be attested to Juliet’s sheer tenacity. A recent breast cancer survivor, Juliet knows how to put up a good fight and is a champion for regional businesses and the untapped expertise in regional areas. ‘Often the education and experience that lies within the regions is overlooked by decision makers in capital cities, adding great expense and additional resource use to manage projects.’ ‘I hope EnviroScience’s national recognition can contribute to breaking down some of the false perceptions that being a bush-based organisation is some sort of barrier to talent.’ Says Juliet. For the future Juliet is keen to develop new products, technologies and staff that will help keep people safe from environmental hazards, both in Australia and internationally. ‘Every day new hazards are being identified, and we strive to be on top of the impacts they can have on the communities where we live and work’. SmartShepherd Announces Availability of their World First Pedigree System for Sheep and Cattle 2017-10-10T02:25:44Z smartshepherd-announces-availability-of-their-world-first-pedigree-system-for-sheep-and-cattle   Media Release: SmartShepherd Announces Availability of their World First Pedigree System for Sheep and Cattle Armidale, NSW, Australia – October 9th,  2017 – SmartShepherd, an agricultural technology company, announced today the availability of the revolutionary SmartShepherd System, which automates the collection of maternal pedigree data for livestock. With a mission to empower farmers to breed better livestock. SmartShepherd has developed a smart tag which substantially decreases the barrier of entry to full pedigree recording and reduction of inbreeding. The SmartShepherd system functions with all large free-range livestock, including sheep, cattle and goats. A recent field trial at Centre Plus, Tullamore, Central NSW has delivered a result of 96% accuracy when compared against existing farmer pedigree records, and this was accomplished within 48 hours. SmartShepherd Co-Founder and CEO Dave Rubie said, “We are very pleased that we have been able to surpass the industry expected accuracy within 48 hours of the smart tags being attached to the sheep, and are excited to make our world-first solution available to livestock farmers.” Centre Plus ram breeding nucleus manager, Mark Mortimer said, “I was able to get the same results in 2 days with the SmartShepherd tags that I would normally expect to get in 15 to 20 days with the pedigree match maker system. I think the real advantage of the SmartShepherd system is that you are not reliant on the sheep coming into water to get your tag read. In wet years I have struggled to get our current system to work. I can see the SmartShepherd system working in all environments and any time of the year.” The Co-founders of SmartShepherd believe their success is due to their winning combination. Dave Rubie worked at Sheep Genetics Australia for 12 years, where he used his extensive technology and breeding expertise to assist farmers in improving breeding outcomes. Glenn Vassallo is a respected IoT (Internet of Things) expert who has worked at Microsoft and the leading IoT platform company ThingWorx, he has also received awards from Texas Instruments for his work with microcontrollers.  Glenn Vassallo said, “I think the results speak for themselves, and are a testament to what can be achieved when the livestock industry and the technology industry combine forces. We are looking forward to building on our success and demonstrating what Australian innovation is all about.” SmartShepherd is taking inquires and orders from their website – http://www.smartshepherd.com.au     Smart Tag  Smart Collar 2017 WHITE PEARL BALL CONTINUES QUEST TO SUPPORT UNDER-FUNDED BRAIN CANCER RESEARCH 2017-10-05T22:21:02Z 2017-white-pearl-ball-continues-quest-to-support-under-funded-brain-cancer-research Sydney, Australia, 6 October 2017: Sydney Neuro-Oncology Group (SNOG) today announced that BANK OF SYDNEY is joining THE WHITE PEARL BALL 2017 as its newest and biggest corporate partner. As part of the Bank’s wider commitment to support the community and charitable organisations, Bank of Sydney will have a significant presence at the Ball and is expected to provide SNOG with significant exposure across its many branches around the State and in ongoing communications with its customers. Having announced that the WHITE PEARL BALL 2017 will take place on November 11th at the Westin Sydney, SNOG will continue its important work in support of brain cancer research. Now in its 3rd year, the event raised $153,000 last year alone through the generous support of guests, donors and sponsors that attended the event. Donations collected at the Ball will fund a new brain cancer research position within SNOG. Established in 2000 by eminent neuro-surgeons, Dr Raymond Cook and Dr Michael Biggs, who were soon after joined by medical oncologist Associate Professor Helen Wheeler, SNOG’s research program is located at the Bill Walsh Cancer laboratory in the Kolling Institute of Medical Research on Sydney’s Royal North Shore Hospital campus. Dr. Cook, Dr. Biggs and Associate Professor Wheeler to this day remain on the Board, directing 100% of donations received to SNOG’s 3 Pillars - Research, Education and Patient Support. Notable contributions have also been made by Assoc. Professor Michael Back, Assoc. Professor Mustafa Khasraw, the recently appointed Dr. Jonathon Parkinson and Board members outside of the medical team. Established by Suzane Peponis-Brisimis in 2015 following the loss of her mother to a brain tumour, The White Pearl Ball has quickly become a much-anticipated event on the Sydney social calendar. “The White Pearl Ball is held in honour of all who have succumbed to brain cancer, those who are currently struggling and all their loved ones. The Ball honours the enormous contribution made by those in the medical profession who treat these patients and support their families and to the researchers who devote their lives to finding solutions,” said Suzane Peponis-Brisimis, Director of SNOG and the White Pearl Fundraiser. In addition to major prize sponsorships, the broader exposure created through the annual charity fundraiser has also seen sponsors such as Alcatel Mobile broadening their involvement with the organisation to include taking up a $35,000 PhD Scholarship, funding promising research by SNOG PhD student Angela Cho. As the leading cause of cancer death in people under 39 years and accounting for more than a third of cancer deaths in children under the age of 10, brain cancer is one of the most under-studied of all cancers. The reality is that brain cancer receives less than 5% of government funds allocated to cancer research funding. “It is truly heart-warming to witness the overwhelming support we receive from our partners and supporters each year, through sponsorships, contributions and donations. Our sincere thanks to all. We are particularly excited about partnering with Bank of Sydney for this Ball and look forward to working closely with the Bank of Sydney team. We also thank Sam Skontos and Alcatel Mobile for the significant donation made at the 2016 Ball and for the ongoing support, as a major prize donor, of the upcoming 2017 Ball.” With the newly signed partnership agreement with SNOG now official, Mr. Michaelas, CEO at Bank of Sydney, was full of praise for SNOG and the important role that it plays. “We would like to congratulate Suzane and her team for all the hard work they put into SNOG. They have inspired Bank of Sydney to get involved, and we want to encourage the community and our customers to support this effort for the well-being of patients whose lives are affected by brain cancer and their families. We are proud of this partnership and we hope that we will help attract more funds and raise awareness for SNOG” said Mr. Michaelas, CEO of Bank of Sydney. The White Pearl Ball will be held at Westin Sydney on November 11th. For tickets, donations, or if you require any further information, please contact Suzane on 0418 238 723 or email her at suzane@wpfundraiser.com.au. About the Sydney Neuro-Oncology Group: The Sydney Neuro-Oncology Group (SNOG) is a charitable organisation that aims to improve the management of brain tumours through targeted research, information sharing, constant scrutiny of treatment options and through education and ongoing support for patients and their families. For more information, go to www.snog.org.au About Bank of Sydney: Bank of Sydney has been operating in Australia under a full Banking Licence since April 2001. With branches in Sydney, Melbourne and Adelaide, we work closely and personally with our customers to understand and exceed their individual needs, which fulfils our vision to become Australia's only true relationship Bank. Bank of Sydney has a remarkable record of investing in and engaging with the broader community as part of its corporate social responsibility initiatives. For further information go to https://www.banksyd.com.au/ Gut health, immunity and relief from atopic dermatitis for infants: powerful bacteria strain in new consumer health products 2017-08-23T22:38:32Z gut-health-immunity-and-relief-from-atopic-dermatitis-for-infants-powerful-bacteria-strain-in-new-consumer-health-products A potent strain of probiotic bacteria scientifically and clinically demonstrated to reduce eczema symptoms in infants, colonise the gastrointestinal tract and help improve immunity for adults including endurance athletes is now available in a new range of Australian health products. The probiotic strain, Lactobacillus fermentum VRI-003, was originally isolated from a woman with robust gastrointestinal health and is owned by the Australian life sciences company Bioxyne. Lactobacillus fermentum VRI-003 is trademarked ‘PCC®’. This month Bioxyne launched three products formulated with PCC® – Progastrim® for gut health and immunity, Progastrim® + Vitamin C to help reduce the severity and duration of colds and flu symptoms, and proTract® for infants with atopic dermatitis (eczema). Bioxyne’s Scientific Director, cell and molecular biologist Dr Peter French, first started working on the connection between gut microbiome and immune health in 2002. “PCC® has an advantage over many other strains on the market because it produces a thick polysaccharide coat that causes the bacteria to clump, protecting the bacteria from stomach acid and bile and helping it adhere to the walls of the intestinal tract,” Dr French said. “We know from laboratory studies that PCC® is capable of colonising the intestinal tract and stimulating the areas of immune tissue in the small intestine known as Peyer’s Patches. It exhibits superior survival to other probiotics in the acidic (pH 2-4) environment found in the stomach and large intestine and it inhibits a number of human gastrointestinal pathogens.” In double blind, placebo-controlled studies*, PCC® has demonstrated: Reduction of the duration and severity of respiratory infections Reduction of the symptoms of moderate to severe atopic dermatitis (eczema) in infants Boosting of the immune response to the FluVax (flu vaccinations) improved bowel PCC® has a thick, clumpy coat which gives it a survival advantage over other, better known probiotics such as Lactobacillus acidophilus Earlier this year the Therapeutic Goods Administration (TGA) reviewed the evidence supporting the claims for PCC® ’s ability to help improve eczema symptoms in infants and confirmed that the claims comply with the requirements for listing the product on the Australian Register of Therapeutic Goods (ARTG). “Scientists are increasingly proving the connection between the gut microbiome and general health and wellbeing, in ways that extend far beyond just the gastrointestinal tract,” said Dr French. “The question now isn’t whether probiotics are good for you, but which probiotics should be consumed and for what purpose. “Consumers should look for probiotics that are of human origin, resistant to acid and bile, and that have been scientifically and clinically tested for their health claims. We are particularly pleased that the Therapeutic Goods Administration (TGA) earlier this year reviewed the evidence supporting the claims for PCC® ’s ability to help improve eczema symptoms in infants and confirmed that the claims comply with the requirements for listing the product on the Australian Register of Therapeutic Goods (ARTG). Bioxyne’s PCC® products – Progastrim® (RRP AUD$29.95), Progastrim® + Vitamin C (RRP AUD$32.95) and proTract® for atopic dermatitis (RRP AUD$27.95) - can be purchased online at www.bioxyne.com *References to clinical studies cited: Prescott S, Dunstan JA, Hale J, Breckler, Lehmann LH, Weston S, Richmond P, 2005. Clinical effects of probiotics are associated with increased interferon-gamma responses in very young children with atopic dermatitis. Clinical & Experimental Allergy; 35(12):1557-1564. Weston S, Halbert A, Richmond P, Prescott SL, 2005. Effects of probiotics on atopic dermatitis: a randomised controlled trial. Archives of Diseases in Childhood 90:892-897. Cox AJ, Pyne DB, Saunders PU, Fricker PA, 2008. Oral administration of the probiotic Lactobacillus fermentum VRI-003 and mucosal immunity in endurance athletes. British Journal of Sports Medicine 44:222-226. French P, Penny R, 2009. Use of probiotic bacteria as an adjuvant for an influenza vaccine. International Journal of Probiotics and Prebiotics 4(3):175-180. West NP, Pyne DB, Cripps AW, Hopkins WG, Eskesen DC, Jairath A, Christophersen CT, Conlon MA, Fricker PA, 2011. Lactobacillus fermentum (PCC®) supplementation and gastrointestinal and respiratory-tract illness symptoms: a randomised control trial in athletes. Nutrition Journal 10:30. Breaking News - ASX Listed G Medical Signs Binding MOU for US $67.5M for China Distribution 2017-07-27T00:24:14Z breaking-news-asx-listed-g-medical-signs-binding-mou-for-us-67-5m-for-china-distribution ASX Announcement 27 July 2017 G MEDICAL SIGNS BINDING MOU FOR CHINA DISTRIBUTION VALUED AT US$67.5M •Binding MOU signed with Shandong Boletong Information S&T Co. Ltd. •Agreed terms include call centre cooperation and a minimum purchase order of Smartphone Prizmaunits within the first year. •Medical and ancillary support via Nurse and Physician staffed call centres and ‘Cloud’ services. Mobile health and e-health company G Medical Innovations Holdings Ltd (“G Medical” or the “Company”) is pleased to announce it has executed a Binding Memorandum of Understanding (“Agreement”) between its subsidiary G Medical Innovations Asia Limited and Shandong Boletong Information S&T Co. Ltd. (“Boletong”), for the distribution of G Medical’s products and for call centre and ‘Cloud’ services in the People’s Republic of China. G Medical Smartphone Prizma Purchase Order Pursuant to the terms of the Agreement, Boletong has agreed to purchase a minimum quantity of units within the 1st Year of the G Medical Smartphone Prizma, and to provide associated support services for a minimum period of 60 months. Boletong will pay a pre-determined price for each unit, with the value of the agreement based on the minimum commitments being no less than US$67,500,000. The obligation to acquire the units commences on the granting of the CFDA certification to G Medical, which is currently in process. Support Services 1) Medical Services: Pursuant to the terms of the Agreement, Boletong and G Medical will set up a medical call centreproviding support services from 50-60 Nurses and 3-5 General Practising Physicians. Boletong will be responsible for the recruitment of the Nurses and General Practising Physicians, andthe establishment of the call centre. 2) ‘Cloud’ Subscription and Support Services: Pursuant to the terms of the Agreement, Boletong and/or G Medical will provide; a) Automated Cloud algorithm interpretation services, for biomedical signals 20170727_GMV - Binding MOU for China Distribution Page 2 of 3 b )Level 1 services including, Live and/or automated end-user technical support c) Level 2 services including, hardware (device) support, replacement/repairs Marketing and advertising G Medical agreed to contribute an immaterial portion of the per unit price as marketing and investment for Boletong's promotion of the products and services in China, with such payments to be set-off against payment of the purchase orders by Boletong. Non-competition Boletong and its associations are subject to non-competition restraints for the period of the Agreement, and ending five years after its termination (unless G Medical is found by a Court to have breached the Agreement). These non-competition restraints extend to competing with the products or services of G Medical. G Medical CEO Dr. Yacov Geva, commented: “I am extremely pleased to announce yet another significant relationship for G Medical within the ever-growing and lucrative Chinese territory. To have further increased our purchase commitment for our G Medical Smartphone Prizma devices, over and above our existing agreements, is an exceptional outcome with a key partner in Boletong. This adds further to our robust, multi-year revenue stream for the Company, particularly within the first year of a CFDA approval being granted”. “I have met with the executives of Boletong, and whilst in China have visited their facilities and operations. Boletong operates in 16+ provinces and works with the National Public Health care system and acts as a distributor of medical services for the government. Boletong is currently working with several large healthcare organisations such as Wanda, a medical company which is positioned in the top three in their area, and along with telecom carriers such as China Telecom. Boletong is also supported through investment from a large and reputable group in Beijing. Our team, has invested more than 3 months in bringing this MOU to fruition, during which time we were able to satisfy ourselves as to Boletong's strong financial position, their key government partnerships in place, and the ability to deliver all aspects under our agreement.” “This relationship is a significant strategic partnership, allowing the roll out the Company’s medical and ancillary support services within the Chinese territory, for both our professional call centre and Cloud based systems”. Ends Corporate Advisors Otsana Capital 108 Outram Street West Perth WA 6005 Telephone: +61 8 9486 7244 www.otsana.com About Shandong Boletong Information S&T Co., Ltd Shandong Boletong Information S&T Co., Ltd. (Boletong) is a hi-tech medical and healthcare company invested by Beijing Honghui Group which has businesses in medicine, investment, drug store automation system and new energy areas, based in China. Boletong focuses on the production and sales of medical devices, membership healthcare management systems and R&D and applications for the National Basic Public Healthcare Project Solution. Boletong is currently one of the top 16 service providers for the national public healthcare system. Boletong is located in Jinan Hi-tech Technology Development Area, Shandong province. Boletong’s website is www.sdboletong.com About G Medical Innovations G Medical (ASX:GMV) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company brings forth the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity. The Company specialises in innovative next generation mobile and e-health solutions and services using its suite of devices and software solutions with a view to driving multiple and recurring revenue streams, across numerous verticals and territories. For more information on G Medical, please visit www.gmedinnovations.com Fellowship supports search for new disease treatments 2017-07-23T22:55:35Z fellowship-supports-search-for-new-disease-treatments La Trobe University and leading Australian biotech company AdAlta have received new funding to identify and develop potential treatments for a range of human diseases using the company’s novel class of drugs, known as i-bodies. La Trobe University’s Dr Chris Hocking has been awarded a Science and Industry Endowment Fund (SIEF) Business Fellowship worth $427,000 ($210,000 from the CSIRO), further strengthening the collaboration between La Trobe University and AdAlta. The SIEF Business Fellowship Program aims to build deeper connections and collaborations between researchers and industry, accelerate the adoption of new ideas and technology, while also helping to grow into larger and more profitable organisations. Furthermore, the program provides practical industry experience for early career researchers. The SIEF Fellowship grant will support Dr Hosking’s work with AdAlta’s Chief Scientific Officer, Professor Mick Foley, at the La Trobe Institute for Molecular Science. “Under the SIEF grant we will screen the i-body library to identify and develop new i-body candidates against difficult to access drug targets, such as complex signalling proteins called GPCRs,” Professor Foley said. “Chris is an excellent candidate for the Fellowship because he has extensive experience working with phage displays and screening libraries. Chris brings significant expertise to the AdAlta team.” La Trobe Pro Vice Chancellor Industry and Engagement, Dr Daniel Grant, congratulated Dr Hosking. “La Trobe recognises the importance of engaging with, and building strong partnerships with, innovative companies,” Dr Grant said. “We have had a longstanding and productive relationship with AdAlta and this Fellowship is a great outcome for both parties.” I-bodies are a promising, novel class of drugs that offer a new and more effective approach to treatment of a wide range of human diseases. AdAlta pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, which was discovered initially in sharks and then developed as a human protein. More: www.AdAlta.com The Genetic Testing Laboratories Expands Portfolio of Clinical Tests 2017-03-08T10:36:31Z the-genetic-testing-laboratories-expands-portfolio-of-clinical-tests Springwood- Queensland – 08/03/17 -Australia based genetic testing company The Genetic Testing Laboratories (also known as GTL Australia) has launched a new range of clinical DNA tests to its existing portfolio in partnership with a leading genetic laboratory in Australia. The company has recently introduced a blood based Allergy test, which analyses various allergy panels and measures the levels of the allergy antibody IgE in response to the allergens tested. GTL Australia has also launched Pharmacogenomic testing, a cutting edge-test which tests an individual’s gene response to certain drug classes as well as an Inherited Disease Panel which covers a person’s genetic predisposition to over 700 diseases. The latest addition to the portfolio is the Post Natal Test which establishes a baby’s risk for 50 inherited disorders and includes information regarding the baby’s ability of metabolizes 20 different drugs. Commenting on this significant venture, GTL’s sales and marketing manager states that “we believe clinical testing and personalized medicine are what medicine and health care is moving towards. The gradual paradigm shift is becoming more obvious with the growing requests we get not only from individuals, but also from doctors and clinics who wish to better advise, treat, prevent and guide their patients through access to various clinical tests such as gluten testing or pharmacogenomic testing.” The Genetic Testing Laboratories notes that is only offers its portfolio of tests following Australian guidelines “the tests must be ordered by a doctor and results sent to doctor. The client can then discuss their results with the doctor. With an ever-growing demand for patient satisfaction, effective treatments and positive outcomes, the company foresees an evolution in the field of clinical tests which will become an integral part of detecting, managing and preventing diseases and illnesses. The company also notes how it is not only the private medical and health sector that can benefit from these tests but public hospitals and other state run health care entities which should seek collaborations with private companies and laboratories that offer these tests because “clinical tests can potentially save millions of dollars and reduce pressure on the public health service which is already under strain in many countries. Having access to such targeted treatments, based on the results of genetic testing, can avoid use of ineffective drugs, over or under prescribing, which amongst many other related issues, just increase the tab on public health care spending” About GTL The Genetic Testing Laboratories offers health, clinical relationship as well as parentage testing services. It is one of the leading companies in Australia, with offices in countries including the United Kingdom. Tech21 brings parents unlimited fun family time with Evo Play 2017-02-21T01:20:13Z tech21-brings-parents-unlimited-fun-family-time-with-evo-play SYDNEY, 21 February, 2017 – Tech21, the leader in impact protection for mobile devices has launched its new range of cases for the iPad in Australia: Evo Play. “Kids + iPads” isn’t always the safest pairing if your iPad isn’t protected, but it can certainly be one of the most fun for inquisitive minds. Whether it’s watching the latest episode of Peppa Pig or navigating through the back garden jungle discovering new wildlife, iPads can open up a world of exploration, but more often than not, a small chip here or a little crack there means that fun can be cut short. Prolong the play time and keep that shiny new look and feel to your iPad even when little fingers have put it through its paces thanks to tech21’s new iPad case, Evo Play. This comfortable and lightweight case has been designed to offer unbeatable drop protection from up to two metres, and with its iconic design, vibrant colours and handy multi-use handle, this case will remove any glimmer of fear you had in handing over your iPad to your children. This case is constructed almost entirely from tech21’s unique material, FlexShock™ Foam, meaning all sides and surfaces are protected from drops as the material moulds snugly to your iPad. Better still, the case is entirely dishwasher safe, so it’s easy to keep clean, and when it’s on your iPad, its sealed outer shell is abrasion/bite resistant, preventing any bacteria from getting in under the surface. “We’ve designed the all-new Evo Play with kids in mind. We know children love to learn, play and explore, and we recognise iPads are a great way for them to do this. However, they may not love your precious iPad back, so Evo Play is there for you,” comments Jason Roberts, CEO, tech21. “Evo Play is lightweight and comfortable for little hands to hold, yet strong enough to keep your iPad safe from tumbles and drops.” Evo Play is available in pink/purple and blue/green colours from tech21.com, RRP $79.95 for Apple iPad mini, mini 2, mini 3 & mini 4, and RRP $109.95 for Apple iPad Air 2. Much like all of tech21’s products, Evo Play comes with a simple promise: it’s rigorously tested to work harmoniously with your iPad. Like the technology it’s designed to protect, it uses the latest science, ingenious design and unbeatable user-friendliness to make advanced impact protection possible. Tech21 calls it ‘Protection Made Intelligent’. ### For further information, questions, or cases for review, please contact: Jim Barker, tech21/Poem Phone: +61 418 163 770 Email: jim@poemgroup.com.au High-res images: Download here About tech21 Since 2005, tech21 has been developing the most advanced, scientifically proven cases and screen shields for mobile, tablet and laptop devices worldwide. Tech21 combines science, engineering and British design to create products that address three core consumer benefits: style, protection and performance. As the brand evolves to continue meeting the needs of its consumers, tech21 has developed the most advanced impact protection material on the market – FlexShock™. The ultra-thin and lightweight material absorbs and dissipates force and can withstand drops up to 4 metres. In addition tech21 puts all its products through a rigorous testing program, and in an industry first has partnered with the National Physical Laboratory (NPL) to develop its testing methodology. This ensures that the tests tech21 products have to pass are overseen by independent experts. Tech21 is the number one case brand in the UK. For more information, visit tech21.com. eVestigator® Cyber Forensics Expert Simon Smith says 'POKÉMON NO' to Augmented Reality 2016-07-26T09:36:16Z evestigator-r-cyber-forensics-expert-simon-smith-says-pokemon-no-to-augmented-reality PRESS RELEASE 26/7/2016 CYBER FORENSIC EXPERT ISSUES NATIONAL SECURITY WARNING EVESTIGATOR CYBER FORENSICS EXPERT SIMON SMITH SAYS 'POKÉMON NO' TO AUGMENTED REALITY Availability for further interview / discussion TV – Aus-Wide – 24hrs notice, Radio – 8 hrs notice –© Simon Smith 0410 643 121 - forensic@evestigator.com.au. Written consent needed to reuse/quote from this release. Contact: Simon Smith. (eVestigator® aka Simon Smith, an expert in Cyber stalking and Cybercrime Investigations and a Master in Computer Digital Forensics says that our children and teenagers are severely at risk of physical, sexual and psychological harm from the use of this game) © SIMON SMITH - EVESTIGATOR® URGENT PUBLIC MEDIA RELEASE © - CREDIT & PERMISSION ASKED FOR IN WRITING BEFORE USE eVestigator®, Computer Forensics Cyber Expert – CHFI, Computer Hacking Forensics Investigator, Private Investigator Phone: 1800 CYBER I, Direct: 0410 643 121 www.evestigator.com.au www.cybersecurity.com.au www.courtexpertwitness.com.au Melbourne, July 26, 2016: Mr. Simon Smith of www.evestigator.com.au, and www.cybersecurity.com.au, a top Australian Computer Forensics expert, Cyber-crime Investigator, cyber-stalking expert and programmer of 25 years knows all too well the other side of what it looks like in a courtroom when somebody is the victim of cyber-stalking or white collar crime. He is often giving forensic evidence or reports in relation to high-tech computer crimes as an expert witness or private investigator. He has also worked on cases involving child pornography and the police, and is a strong advocate against Cyber-bullying, Cyber-stalking and Cyber-crimes civilly and criminally, and has helped hundreds of people attain justice and resolution in many cases, especially involving children and violence and forensic impersonation. As a Commonwealth Appointed Family Dispute Practitioner, with the very difficult job of dealing with awkward family disputes along with his specialised cyber forensic knowledge and cases as a private investigator, he speaks of cases where he has dealt with kidnapping, abductions, cults, poisoning and more. Never, however did Mr. Smith predict that what he calls “Cybergeddon™” would come so soon. Simon explains the term “augmented reality” in the new Pokémon game as going too far. “Imagine walking in a straight line and a cartoon character appears in front of you. That is simply what it is. A technology that draws a computer-generated image on a user's view of the real world (knowing on their phone where they are via the GPS), in this case a character or an object named a Pokémon. It then uses the camera on the back of the phone to paint the background, so it looks like there is a cartoon in your view”. He further says, “the earth is made up of various known areas comprising longitude and latitudes. These are known to the game and randomized, and the object of the game is to find Pokémon and physically step within a meter or so of it to interact, and likewise, collect other objects in the game”. He further explains that “these objects are randomly placed on or around you are on earth without any data verification”. Mr. Smith asks you to imagine your child, or teenage son or daughter walking around with head buried in their phone, jumping complete stranger’s fences, in and out of their neighbourhood, exploring places they shouldn’t be – knocking on stranger’s doors, asking if they can collect a Pokémon from their backyard. Then he asks you to “stop imagining because it is actually happening now”. He then asks you to imagine a “destination” that may be randomly picked in the game for your child to visit. Imagine if one of these stops was say in the case of America, “The Windsor Hotel in Phoenix Arizona”. Would you be concerned if you knew that in this instance, this was a halfway house for sex offenders? He also asks you to not imagine, and says, “Well, that happened too!” Mr. Smith deals with reverse cyber stalking cases all the time. Finally, he asks you to imagine that a group of bullies had a special directory which told them where a victim would be going at a certain time. It would allow them to lay a trap, and wait for the prey. Of course Mr. Smith says, “let’s not imagine - that actually happened too. In fact, only a few days after launch a gamer was robbed at gun point in dangerous unchartered neighbourhoods because the attackers knew he’d be chasing Pokémon they used game bonuses to lure there.” Mr. Smith, both as an IOS and Android programmer and cyber stalking forensic investigator and court expert witness strongly warns the community and rates this at a risk of 10/10 to any parent. He states that It could be used as a directory for stalkers and paedophiles to find children, and cause danger to society in an already understaffed and underqualified area of policing, being organised cyber-crime. Mr. Smith further states that it could even be considered the “Yellow Pages of Children and Teens” for Sex Predators – it could be easily argued that this is in fact no longer “augmented”. Mr. Smith strongly advises everyone to be conscious of the line that has just been crossed – and understand that crime is still crime even if it is hidden in what appears to be a ‘fun super-artificial method of game play’. “It is not a game anymore”, Mr. Smith strongly states. “It’s dangerous, it’s real and it is most likely in the hands of your children now”. Mr. Smith feels very passionate about the dangers he sees, in his expert opinion, he would strongly “recommend parents remove the game after doing further research” as he truly believes it crosses the line by masking serious cybercrime. He finishes by stating that, “It is ironic that people used to be afraid of the psychological effect of what violent artificial games may have on people, now I’m saying backed by evidence and experience, they should really be worried – because it has now crossed over to reality." This is general advice and not to be taken as legal advice and naturally, not all game players are likely to contribute to this conduct, this is an opinion expressed by me raising concern in this area of augmented reality. eVestigator®, Simon Smith Computer Forensics Cyber Expert – CHFI, Computer Hacking Forensics Investigator, Private Investigator © SIMON SMITH - EVESTIGATOR® URGENT PUBLIC MEDIA RELEASE © CREDIT & PERMISSION ASKED FOR IN WRITING BEFORE USE Please consider the environment before printing AUSTRALIA’S LEADING AUTHORS GATHER TO CONDEMN GOVERNMENT’S PLAN TO CREATE A CULTURE OF BOOK THIEVES 2016-05-18T22:21:03Z australia-s-leading-authors-gather-to-condemn-government-s-plan-to-create-a-culture-of-book-thieves Who: Richard Flanagan, Nikki Gemmell, Andy Griffiths, Tom Keneally to lead Alist roll call of Australian and international authors When: Thursday 19 May at 6.45pm – 6.55pm Where: Art Gallery NSW, just before the 16th annual Australian Book Industry Awards begin What: Photo opp with limited vox pops available on request. Don’t close the book on Australian stories. The Australian government is about to make significant changes to copyright, threatening the future of our Australian story. But at what cost to writers, culture and jobs? Guest ABIA presenter and Man Booker Prize winner, Richard Flanagan will deliver a speech in response to the Productivity Commission's Intellectual Property draft report around 10pm during the gala ceremony. ‘Australians deserve that their lives, experiences, country and culture be reflected in the literature that they read.’ - Thomas Keneally For more information, please contact: Emma Rusher T 0423 214 626 | emma@houseofrusher.com Mass Spectrometry for pharma, biotech and research labs 2016-04-05T10:20:29Z mass-spectrometry-for-pharma-biotech-and-research-labs Mass spectrometry, widely accepted as a strong tool for identifying, characterising and purifying compounds was first made known by Dr. Joseph Thompson in the early 1900s. However, the instrumentation and analysis has traditionally needed highly trained technical staff and a highly specialised lab, limiting the reach of the technology. In many cases, lab users are forced to outsource samples to dedicated facilities for MS analysis, increasing costs. Times are changing. Mass spectrometry, once held in the bastion of specialty laboratories, is moving more into mainstream pharmaceutical, biotechnology, and academic laboratories. The power that mass spectrometry provides in the confirmation of compounds in a mixture has become valuable to many areas such as drug discovery purification. To address this shift of use to a broader, non-expert audience, many scientists and instrument companies are rethinking mass spec instrument design. With these redesign efforts, “Mass spec for the masses” (1) has moved from concept to reality.How to move mass spec mainstreamWhile the use of mass spectrometry in the characterisation and confirmation of drug compounds is highly valuable, it is also expensive. Pharmaceutical, biotech and chemical companies, as well as academic labs, are looking at a variety of approaches to control the escalating costs of purification during drug discovery from increasingly complex materials using mass detection techniques. First, they want to decentralise the characterisation process to reduce overhead costs. Usually, chromatographic fractions are sent to a dedicated mass spectrometry lab for further analysis. The large mass spectrometers used require specialised lab space because of their size, their system requirements, and the noise they generate. These instruments also need highly trained personnel to run them and highly trained service engineers to maintain them. For decentralisation to work, mass spectrometry instrumentation must become smaller in size so it easily fits into any chemistry lab. It also must become easier to use to increase the accessibility of the instrument to entry-level spectroscopists and other less experienced lab personnel. A push-button solution is needed that requires less formal training. Next, companies want to decrease the cost of ownership associated with mass spectrometers. Traditional mass spectrometers use large amounts of resources such as power and nitrogen. More importantly, many issues affecting the performance of a mass spectrometer need much more involved repairs, typically requiring a scheduled visit from a field service engineer. The instrument downtime can generate delays for characterisation of samples, impacting productivity and increasing costs. As Alessio Zammataro, Product Manager and Applications Scientist for chip-based mass detection technologies at Microsaic Systems noted, “There is higher demand for real-time techniques using less complex technologies.” The VERITY 1900 MS Detector is easily incorporated with Gilson’s preparative HPLC systems. With a mass range of 50–800 amu and the ability to collect full scan signals and up to four SIM channels simultaneously, the VERITY 1900 MS Detector will become a powerful component of the lab workflow for both small and large molecule identification. Mass detection power that fits in the palm of your handA new breed of mass detectors is currently focusing on meeting some of these needs through instrument miniaturisation. However, as Alessio Zammataro pointed out, “Smaller is a challenge,” given constraints of electronics, physiochemical laws and intellectual property. The VERITY 1900 MS Detector from Gilson offers a new approach that overcomes some of the constraints to miniaturisation. The VERITY 1900 MS Detector relies on proprietary micro-electro-mechanical systems (MEMS) technology developed by Microsaic Systems. The result is the ionchip®, a palm-sized, chip-based mass detector component that has detection power similar to the larger single quadrupole mass spectrometers. The use of the innovative chip-based mass detector helps to shrink the overall VERITY 1900 MS Detector footprint, simplifies the complexity during operation and maintenance, and offers reduced cost of ownership so the instrument can easily be accommodated in a non-specialised lab. The VERITY 1900 chip-based mass detector, through integration with Gilson’s TRILUTION LC software or Glider Prep software, can be programmed by simply entering in one or many target masses. Gilson’s robust and proven HPLC systems do the rest, collecting fractions based on this simple target, which makes the system easier to use by less experienced lab personnel. As Thomas Rawlins, Associate Product Line Manager at Gilson summarised, “At Gilson, we know that scientists want to produce verifiable data in a comfortable laboratory environment. In partnering with such an innovative company (Microsaic Systems), we can enable any chemist to verify the molecular weight of their analyte of interest without disrupting their quality of life in the lab.” Parallel analysis shortens drug development times In a traditional drug purification workflow, preparative liquid chromatography (LC) fraction collection is typically monitored by optical methods such as ultraviolet/visible light (UV/VIS). However, UV/VIS is limited and uncertainty usually exists over the exact contents of a fraction and the purity of the sample. This uncertainty leads to a second stage in the workflow: precise identification of the compound(s) in the fraction and their purity through single quad mass spectrometry at a separate specialised lab. This second phase results in additional time and money. By adding the VERITY 1900 MS Detector to the drug purification workflow, the monitoring of the collected LC fractions is done with both optical and mass detection (UV/VIS and MS) in tandem, allowing fractions to be clearly identified and the purity determined in a single step. Running the UV/VIS and MS detection in parallel eliminates the additional time required for offline mass spec analysis and the necessity for a specialised lab dedicated to that analysis. Time savings due to mass detection during the initial step allows fraction collection to be more specific, resulting in fewer fractions to process later. Easier Maintenance VERITY 1900 MS Detector is a Single Quadrupole Mass Spec Detector with Integrated Splitter and Make-up Pump The VERITY 1900 MS Detector also decreases costs associated with ownership, as it has fewer system requirements for resources such as power and nitrogen. The system is also easier to maintain (e.g., no pump oil changes are necessary), and instrument downtime is significantly reduced, improving productivity and saving money. Many routine maintenance items are also customer serviceable, eliminating the need for a service visit. If a rare performance issue arises, one usually only needs to swap in a new chip to fix the issue. Summary As Alessio Zammataro summed up, “What we have achieved with this product is to maintain the standard performance of a general mainframe single quad benchtop mass spec, but have reduced its running costs and footprint.” Thomas Rawlins also noted, “I am excited to offer scientists a product that really changes the way they think about MS technology. With a chip-based mass detector, the site requirements, maintenance costs, and footprint become more similar to a basic UV/VIS detector than a traditional single quad MS.” The easy-to-use single quad VERITY 1900 MS Detector with its proprietary chip-based technology frees the mass spec from a dedicated specialised lab, allowing mass detection to move into the mainstream.  For more information on the Gilson VERITY 1900,Please contact our team of Laboratory experts byEmail: automation@johnmorris.com.auFree call AUS. 1800 251 799 and NZ  0800 651 700NEW WEBSITE: www.johnmorrisgroup.com/AU/Laboratory NanoRam now complies with new European Pharmacopeia revisions 2016-04-03T06:47:10Z nanoram-now-complies-with-new-european-pharmacopeia-revisions B&W Tek, a mobile spectroscopy solutions company delivering lab quality Raman, LIBS and NIR solutions through user-friendly mobile platforms, is proud to announce full compliance of the award-winning NanoRam® series of handheld Raman spectrometers to the latest revision of the European Pharmacopeia chapter on Raman spectroscopy. In recent years, Raman spectroscopy has become an increasingly popular method for the identification and verification of materials in the Pharmaceutical Industry. This growing popularity along with the regular use of such instruments has led to the European Pharmacopoeia Commission to revise its General Chapter on Raman Spectroscopy (2.2.48), published in Supplement 8.7, to now include handheld Raman spectrometers. These changes will go into effect on April 1, 2016. With this update, the European Pharmacopeia will include specific details regarding an update on the reference standards used for verifying wavenumber scale. According to a press release issued by the European Directorate for the Quality of Medicines & Healthcare (EDQM), cyclohexane has been kept, while polystyrene and paracetamol have replaced indene and naphthalene. “B&W Tek is ready for these updates, and we’re embracing the guidelines for published wavelength shift tolerances for polystyrene, paracetamol and cyclohexane, specifically for handheld Raman,” said Dr. Katherine Bakeev, Director of Market and Customer Development at B&W Tek. The NanoRam is an intuitive, state-of-the-art instrument used for nondestructive identification and verification of materials such as APIs, excipients and intermediates. With a wide variety of sampling accessories, a high resolution touchscreen interface and an easy-to-use software, the NanoRam can be used by non-technical and highly-technical users alike to identify samples and expedite materials through the manufacturing lifecycle. In accordance with these revisions, the NanoRam acceptance tests have been updated to meet the April 1 adoption date and the recertification protocols will also comply with these new regulatory standards. To learn more, visit the European Pharmacopeia website by clicking here or read the EDQM January press release by clicking here. To learn more about the NanoRam, click here.   VIDEO: NanoRam Raman spectrometer IDs raw material faster  Need to know more about the B&W Tek NanoRam ?Talk to our experts in the Laboratory team todayFreecall AUS. 1800 251 799 and NZ. 0800 651 700Email: automation@johnmorris.com.auNEW WEBSITE: www.johnmorrisgroup.com/AU/Laboratory About B&W Tek John Morris Scientific supplies B&W Tek, a mobile spectroscopy solutions company delivering lab quality Raman, LIBS and NIR solutions through user-friendly mobile platforms. B&W Tek provides solutions for the pharmaceutical, biomedical, physical, chemical, safety, security and research communities. Their commitment to innovative solutions has made B&W Tek a leader in Raman spectroscopy solutions. Fluidic Factory: Dolomite launches 3D fluidics printer 2016-03-29T11:13:02Z fluidic-factory-dolomite-launches-3d-fluidics-printer Dolomite, a world leader in microfluidics innovation, has just released its innovative Fluidic-Factory available from John Morris Scientific. As the first commercially available 3D printer for fluidically-sealed devices, the Fluidic factory offers fast and dependable printing from as little as $1.33 per device. Using robust and translucent cyclic olefin copolymer (COC), this makes it simple and affordable to 3D print devices for practically any application. The Fluidic Factory is designed for ultimate ease of use, enabling rapid prototyping of fluidically-sealed devices such as chips, sensor cartridges, fluid manifolds, valves, connectors and medical devices. Its intelligent software and innovative hardware ensure reliable sealing of fluidic paths, allowing the creation of precise channel geometries and various features not possible using etching, embossing, moulding or machining techniques. Users can choose a design from the selection in the Fluidic Factory's Design Library, or create and print their own unique devices using virtually any CAD software. With this complete design flexibility, the Fluidic Factory is ideal for a wide range of applications, including organ-on-a-chip, point-of-care diagnostics, drug development, education, chemical synthesis, and analytical and biomedical assays. The Fluidic-Factory features a replaceable head and bed, and upgradeable software to enable future functionality e.g. on-line chip design file shop, printing alternative polymers, high definition printing, micromilling, fluid dispensing, bio-printing. Fluidic Factory 3D printing method Fluidic Factory uses FDM (fused deposition modelling) method to melt the polymer at high temperatures and eject through the nozzle to the print bed which then solidifies at temperatures below 75°C. Reliable fluidic sealing Fluidic Factory has been designed for reliable sealing even in pressures of up to 10-20 bar (dependent on design). Intelligent software:The desktop PC software analyses the 3D geometry of the device and identifies the internal voids and surfaces. The print paths are then created from the inside of the device outwards and the print head deposits filaments in a continuous, leak-proof manner. Inductive heating:Fluidic Factory's clever design allows filaments to melt together when depositing on top of each other. A small volume of polymer is melted to a fluid state at very high temperatures and only held a few seconds before ejecting and depositing in a 'squashed' manner. This ensures excellent adherence, optimal polymer quality and leak-free channels. 'Squashed' bead method*:Fluidic Factory uses a 'squashed' bead method when depositing beads as opposed to many traditional FDM printers which deposit beads in circular cross-sections. The system is optimised for fluidic sealing. *FDM printers eject the molten polymer, which cools down and solidifies. What is ejected is called a bead. The size of the bead depends on the speed that the nozzle is moving, the nozzle diameter and the rate at which the polymer is ejected. Unique properties of COC (cyclic olefin copolymer) Fluidic-Factory is the world's first COC printer and the first printer in the world able to fabricate fluidically sealed devices. COC has many benefits over other polymers: COC is FDA approved Optically transparent Non-auto fluorescent Excellent resistance towards water-soluble chemicals, acids, alkalis and alcohols Biocompatible Very low water absorption Compatible with various sterilising processes Excellent mechanical properties allowing more realistic prototype manufacturing Channel geometries Circular, triangular or rectangular channel geometries can be printed (dependent on the mode of printing). Other cross-sections are also possible. Intuitive user interface and workflow Fluidic Factory features a touch screen and USB drive to enable easy transfer of print files from a PC. Once the USB is inserted into the Fluidic Factory, the file becomes available to select and print. Once printing is started, the screen displays the time left to print, real-time status and filament use. Print files and Fluidic Factory Software Print files are open format files and may be downloaded from the Design Library. Designs can also be created by CAD software and then saved as a .stl file, which carries information about the surfaces of the model. The Fluidic Factory PC software accepts .stl files and outputs print files (.phff). After importing a .stl file, the PC software creates a graphic illustration of the device. It then illustrates 2D slices, a slice at a time, reconstructed from the .stl information. The user is able to visually inspect the 2D slices to understand the print path of the print head. During this stage, the user is also able to adjust the model to decide the print orientation. The user can scroll through the layers, and once satisfied, finalise the creation of the print file. This file is then copied to a USB flash drive and connected to the PC. To find out more, please see our brochure:Dolomite Fluidic Factory 3D Printer     Want to know more about Dolomite instrumentation?Our Automation Solutions team would love to hear from youPhone free call AUS 1800 251 799 and free call NZ 0800 651 700Email:  automation@johnmorris.com.auNEW WEBSITE: www.johnmorrisgroup/au/Laboratory New Masterflex L/S Digital Miniflex Pump Systems by Cole-Parmer 2016-03-29T11:07:36Z new-masterflex-l-s-digital-miniflex-pump-systems-by-cole-parmer Compact digital pumps for low flow transfer and dispensing deliver the easy use interface researchers have waited for. The new Masterflex L/S Digital Miniflex Pump Systems are complete systems containing both a drive and pump head. The precision digital drive offers a maintenance-free high accuracy motor and an icon-driven menu allows quick, intuitive programming and setup. The high-contrast graphical LCD shows operating parameters: flow rate, drive speed, continuous run, and copy dispense, allowing you to view pump performance continually. The brushless motor offers ±0.1% speed control accuracy with a 3000 to 1 turndown ratio for a wider flow range. Dispensing features include a copy/repeat setting with programmable batch count and a programmable dispense interval that allows hands-free dispensing and filling. An integrated open-head sensor shuts down the drive if the pump head is opened while running. Remote control capabilities allow easy integration into automated processes. Created for transferring, feed, sampling, or filling applications in laboratories and research settings, the new pump systems deliver repeatable low flow rates with flow ranges of 0.004 to 315 mL/min (depending on the model and tubing size selected). Pumps operate with continuous tubing to save costs by eliminating leakage and the need for fittings or connections, thus providing a cleaner fluid path. Single- and dual-channel models are available. Cole-Parmer is a leading global source of laboratory and industrial fluid handling products, instrumentation, equipment, and supplies. John Morris Scientific supplies Masterflex L/S Digital Miniflex Pumps and Cole-Parmer product lines in Australia, New Zealand and the South West Pacific, including popular brand names such as Oakton, Digi-Sense, Environmental Express, Ismatec, and more. Want to know more about a Masterflex L/S Digital Miniflex Pump?Our Technical Experts would love to hear from youAUS Freecall Ph. 1800 552 724 or  NZ Freecall Ph. 0800 651 700Email: info@johnmorris.com.auNEW WEBSITE: www.johnmorrisgroup.com/AU/ColeParmer   Want Laser Particle Sizing at the Press of a Button? 2016-03-21T11:20:54Z want-laser-particle-sizing-at-the-press-of-a-button Simplify particle measurement with the latest Fritsch Laser Particle Sizer ANALYSETTE 22 NanoTec. Designed for research and development professionals in production and quality control. Simply start the programme, select an SOP and include the sample and the process completes automatically. The system is designed for easy operation, short analysis periods and consistently duplicable results. The very large measuring range from 0.01 µm to 2100 µm of the ANALYSETTE 22 NanoTec results from the combination of two lasers with two different measuring cell detector spacings: large particles are detected using an infrared laser with a large distance to the measuring cell, for small particles a green laser with a small distance to the cell is used, which permits the detection of the forward scattered light up to a scattering angle of 65°. The measurement of smallest particles down into the nano range is performed by the green laser light for backward scattering. Specially arranged detectors ensure this. The ANALYSETTE 22 NanoTec consists of a compact measuring unit that can be quickly and easily combined with different dispersion units for dry or wet measurement. Select the wet dispersion unit for wet measurements of solids and suspensions. For dry measurements of not too fine, free-flowing materials use the dry dispersion unit with efficient degradation of agglomerates. For dry measurement of agglomerates or free-flowing materials, choose the falling chute. The measuring cells of the ANALYSETTE 22 dispersion modules are located in practical cartridges that can be exchanged with a single motion when switching between wet and dry measurement, without changing any hoses or modifying the instrument. The ANALYSETTE 22 NanoTec software contains completely predefined Standard Operating Procedures (SOPs) for nearly all typical measurement tasks, making operation especially easy. Via a well-arranged input mask, you are completely free and flexible in modifying these SOPs to perfectly suit your measurement requirements. For the control, recording and perfect evaluation of your measuring results your ANALYSETTE 22 NanoTec is delivered with a computer on which the Fritsch MaS control software is already fully installed. The software MaS control is easy to learn and guides you through the entire measurement process in a largely self-explanatory manner. Read our full FRITSCH brochure for the ANALYSETTE 22 Find out more about FRITSCH instruments fromOur Lab Core Instruments teamPhone free call: AUS 1800 251 799  and free call NZ 0800 651 700Email: info@johnmorris.com.au John Morris Scientific supplies Fritsch an internationally respected manufacturer of sample preparation and particle analysis equipment. Founded in 1920 and headquartered in Idar-Oberstein Germany. All Fritsch instruments offer highest dependability with innovative technology in combination with simple operation. Fritsch are specialists in sample, milling, sieving and dividing as well as particle size and distribution characterisation.